Mabion S.A., a biopharmaceutical company, provides contract development, analytics, and manufacturing services for biologics in Poland. It offers drug substance manufacturing, process development, analytics, and cell line development services. The company also provides medicines for cancer, autoimmune diseases, rare diseases, and other diseases. The company was founded in 2007 and is headquartered in Konstantynów Lódzki, Poland.
Frequently asked questions
What sector does Mabion S.A. (MAB) operate in?
Mabion S.A. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Mabion S.A. (MAB) current stock price?
As of the latest data, Mabion S.A. stock price is PLN 7.57, with a previous close of PLN 7.56. Mabion S.A. gained PLN 0.01 in the last trading session, representing a 0.13% increase.
What is Mabion S.A. (MAB) current market capitalization?
Mabion S.A. market cap is approximately 122.35 million.
What is Mabion S.A. (MAB) Earnings Per Share (EPS)?
The trailing EPS is -PLN 3.53.
What is Mabion S.A. (MAB) EBITDA?
Mabion S.A. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -7.29 million.
Does Mabion S.A. (MAB) pay dividends?
No. Mabion S.A. does not pay a dividend.
What is Mabion S.A. (MAB) beta (volatility) score?
Mabion S.A. has a beta of 0.368, indicating lower volatility than the overall market.